Too Long Didnt Read (TLDR)
Brief summary of DSIP peptide.
DSIP, or delta sleep-inducing peptide, is a research-use neuropeptide that the research community most often associates with sleep architecture, opioid and alcohol withdrawal context, and stress-response questions.
It is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit brain in 1974 and best known for early reports of promoting delta-wave EEG activity.
The strongest human evidence comes from small placebo-controlled studies in chronic insomniacs from 1981-1987, with sample sizes of 6-14 and mixed results across studies.
DSIP is not FDA-approved and is on the FDA's Category 2 do-not-compound list as of September 2023; the FDA refers to it as Emideltide and has scheduled a PCAC review for July 2026.
I verified the FDA Category 2 listing directly on FDA.gov and cross-checked the older Schneider-Helmert insomnia trials in the original European Neurology and Experientia papers.
Definition
What DSIP is
DSIP, or delta sleep-inducing peptide, is a small naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of about 849 daltons. It was first isolated in 1974 by Swiss researchers Monnier and Schoenenberger from the cerebral venous blood of sleeping rabbits.
The peptide is named for an early observation that infusion produced delta-wave EEG activity, which is the slow brain-wave pattern that dominates the deepest stages of non-REM sleep. As of May 2026, DSIP is not FDA-approved for any human indication. The FDA refers to it in the Federal Register as Emideltide and placed it on the Category 2 list of bulk drug substances that may not be compounded in September 2023.
Mechanism
How DSIP works
Despite a 50-year research record, DSIP's exact receptor and mechanism are not fully established. Reviews describe it as a sleep-modulating peptide rather than a sedative, with effects that are stronger in disturbed sleep than in healthy subjects.
Reported pathways include possible interactions with NMDA receptors, alpha-adrenergic signaling, and the hypothalamic-pituitary-adrenal axis. DSIP-like material has been detected in the hypothalamus, limbic system, pituitary, and gut, and the peptide can cross the blood-cerebrospinal fluid barrier.
Older reviews note a U-shaped activity curve where small or short doses produced the strongest reported effect, while higher or longer infusions did not.
- Possible NMDA-receptor interaction
- Alpha-adrenergic and HPA-axis signaling
- Mechanism not formally established in modern human studies
Research use
What the research community uses DSIP for
The practical research-use intent clusters around DSIP are sleep, withdrawal context, and stress. The most consistent association is with sleep architecture: research interest centers on whether DSIP changes slow-wave sleep, total sleep time, or the experience of disturbed sleep, rather than on producing sedation.
A second cluster is opioid- and alcohol-withdrawal research. Russian and Eastern-European groups studied DSIP in case-series and open-label withdrawal contexts in the 1980s and 1990s, and that line of work is part of why the FDA's July 2026 PCAC review of Emideltide includes opioid withdrawal as a proposed indication. A third cluster is stress and HPA-axis research, where DSIP has been studied as a possible cortisol or stress-hormone modulator.
Separating popularity from proof matters here. DSIP is widely discussed in research-use peptide write-ups, but the modern, well-powered, FDA-recognized clinical evidence is small. The boundaries below describe the evidence as it actually exists, not the language the supplement and clinic markets sometimes use.
- Sleep architecture and slow-wave sleep
- Opioid and alcohol withdrawal research
- Stress, HPA-axis, and cortisol modulation
- Pain modulation (early-stage and inconsistent)
Evidence
What the research shows
The strongest human evidence comes from small placebo-controlled studies in chronic insomniacs run between 1981 and 1987 by Schneider-Helmert and colleagues, published in Experientia and European Neurology. These trials used 25 nmol/kg of DSIP intravenously across short courses of four to seven nights with sample sizes of 6 to 14 subjects. Results were mixed: some studies reported improved total sleep time, fewer awakenings, and better daytime alertness, while other 1987 polysomnographic work reported that the differences from placebo did not reach clinical significance.
Preclinical evidence is more extensive. Studies in rabbits, rats, mice, and cats have reported delta-wave EEG effects, motor recovery in rat focal-stroke models (a 2021 paper in Molecules), and neurotransmitter changes in PCPA-induced insomnia mouse models (a 2024 paper in Frontiers in Pharmacology). Reviews from 1984, 1986, and 2006 summarize the broader animal data.
The major evidence gap is the absence of any modern, large-sample, FDA-recognized RCT. The 1980s human studies were small. The PCAC review scheduled for July 2026 is the next formal regulatory review point and will assess proposed compounding for opioid withdrawal, chronic insomnia, and narcolepsy.
Context
How DSIP compares
DSIP is most often compared to melatonin, Epitalon, and prescription sedatives. Melatonin is an OTC hormone supplement that mainly shifts sleep timing through the circadian system. Epitalon is a research-use tetrapeptide studied for circadian and longevity markers, with sleep effects largely anecdotal. Benzodiazepines are FDA-approved prescription drugs that act as GABA-A agonists; they reliably produce sedation but tend to degrade sleep architecture.
DSIP's research framing is distinct from all three: it is described as a sleep modulator that may interact with multiple pathways and shows the strongest reported effect in already-disturbed sleep. These compounds are not interchangeable.
Boundaries
Safety and regulatory status
Older trials and reviews describe DSIP as well tolerated at the doses studied, with transient mild headache, nausea, or dizziness in some subjects. Long-term human safety has not been formally established, and the data set remains small.
Theoretical risks flagged in regulatory review include immunogenicity (the FDA's stated concern in the Category 2 listing), interaction with sedating medications, and unknown effects in pregnancy, lactation, and pediatric populations. Quality-control risk is also real for any research-use peptide and is part of why the FDA listed DSIP as Category 2.
As of May 2026, DSIP is not FDA-approved for any human indication. It was placed on the FDA's Category 2 list of bulk drug substances with significant safety risks in September 2023, and the Pharmacy Compounding Advisory Committee is scheduled to review Emideltide in July 2026 for proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy. Regulatory status can change; the FDA Category 2 page should be checked directly for the current listing.
Next
What to review next
Readers researching DSIP often want protocol-level detail (dosing, reconstitution, supplies). Peptide Advisors does not publish dosing protocols. For protocol-focused research, see Peptide Dosing Protocols at https://www.peptidedosingprotocols.com/.
Useful primary sources include the Schneider-Helmert 1981 and 1987 papers, the Kovalzon 2006 "unresolved riddle" review, the 2024 Frontiers paper on the DSIP-CBBBP fusion peptide, and the FDA Category 2 bulk-substances list. Within Peptide Advisors, related guides on sleep- and stress-adjacent compounds (Selank, Semax, Epitalon, MOTS-c) help map DSIP into the broader research landscape.
FAQ
DSIP FAQs
Short answers for the reusable peptide detail template.
What is DSIP peptide?
DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide first isolated from sleeping rabbits in 1974. It is named for early reports of promoting delta-wave EEG activity. The FDA refers to it as Emideltide.
What is DSIP used for in research?
Research interest clusters around sleep architecture (especially slow-wave sleep), opioid and alcohol withdrawal context, and stress and HPA-axis modulation. The strongest human evidence is in chronic insomnia, and even that data set is small.
Is DSIP FDA-approved?
No. As of May 2026, DSIP is not FDA-approved for any human indication. It was placed on the FDA's Category 2 do-not-compound list in September 2023, and the FDA's Pharmacy Compounding Advisory Committee is scheduled to review it (under the name Emideltide) in July 2026.
What does "Emideltide" mean?
Emideltide is the name the FDA uses for DSIP in the Federal Register. The two terms refer to the same nine-amino-acid peptide.
What does the human evidence on DSIP actually show?
Small placebo-controlled studies in chronic insomniacs from 1981-1987 reported modest improvements in total sleep time and daytime function, and other studies in the same era reported that differences from placebo did not reach clinical significance. Sample sizes were 6-14 subjects. There is no modern large RCT.
How does DSIP compare to melatonin?
Melatonin is an OTC hormone supplement that mainly shifts sleep timing via the circadian system. DSIP is a research-use peptide that has been described as modulating sleep architecture rather than sedating. They work through different pathways and are not interchangeable.
What is a typical DSIP dosing protocol?
Peptide Advisors does not publish dosing protocols. For protocol-focused research on DSIP, see Peptide Dosing Protocols at https://www.peptidedosingprotocols.com/.
Is this DSIP guide medical advice?
No. This guide is an educational research summary and is not medical advice. DSIP is not FDA-approved and is on the FDA Category 2 list. Talk to a qualified clinician before any peptide use.
References
/ 10DSIP sources & citations
Primary sourcesPrimary clinical literature and pharmacology references behind this guide.
- 01
Delta-sleep-inducing peptide (DSIP): a review.
Graf MV, Kastin AJ. · Neuroscience and Biobehavioral Reviews · 1984
Foundational review describing DSIP as a nonapeptide of MW ~849 with U-shaped activity curve and broad physiological effects beyond sleep.
- 02
Delta-sleep-inducing peptide (DSIP): an update.
Graf MV, Kastin AJ. · Peptides · 1986
Update review summarizing additional sleep and extra-sleep findings and proposed adrenergic mechanism.
- 03
Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
Kovalzon VM, Strekalova TV. · Journal of Neurochemistry · 2006
Skeptical mechanism review acknowledging the open questions around DSIP's natural occurrence and physiological role.
- 04
The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.
Schneider-Helmert D, Schoenenberger GA. · Experientia · 1981
Six-subject IV study reporting longer sleep duration and better sleep quality in chronic insomniacs at 25 nmol/kg.
- 05
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.
Schneider-Helmert D. · European Neurology · 1987
Fourteen-subject double-blind crossover reporting improved night sleep and daytime alertness across a 7-night course.
- 06
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.
Salgado-Puga K, et al. · European Neurology · 1987
Polysomnographic study reporting that DSIP-vs-placebo differences did not reach clinical significance — important counterweight to positive trials.
- 07
Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke.
Khvatova EM, et al. · Molecules · 2021
Modern preclinical paper showing intranasal DSIP improved rotarod motor performance in a rat focal-stroke model.
- 08
Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
Wang Z, et al. · Frontiers in Pharmacology · 2024
Recent preclinical study showing DSIP-CBBBP fusion peptide modulated 5-HT, glutamate, dopamine, and melatonin in a PCPA insomnia mouse model.
- 09
Delta sleep-inducing peptide.
Cox JR. · European Journal of Anaesthesiology · 2001
Anaesthesiology review describing DSIP as a sleep-promoting rather than sedating substance, with stronger effect in disturbed sleep.
- 10
Certain bulk drug substances for use in compounding that may present significant safety risks.
U.S. Food and Drug Administration. · FDA.gov · 2023
Primary regulatory source for DSIP's Category 2 listing (September 2023) and the FDA's stated immunogenicity concern.
Medical Disclaimer
This article is provided for educational research purposes only and should not be treated as medical advice. DSIP is not FDA-approved. Compounded versions should be used only with appropriate physician oversight. Do not begin any peptide protocol without speaking with a licensed healthcare provider, and remember that individual responses can vary significantly.
Written by
Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Garret personally researches, writes, and reviews every guide on Peptide Advisors. Each page is sourced from peer-reviewed clinical trials, systematic reviews, and regulatory filings — with every claim cited and the source hierarchy published openly.
Last reviewed